scout
News|Articles|December 8, 2010

ASH 2010 Homepage Header

Oncology NEWS International reports on critical information from the American Society of Hematology's 52nd annual meeting.

 

  • Rituximab instead of ‘watch and wait’ policy in asymptomatic follicular lymphoma causes controversy

  • Ofatumumab generates high response rates in refractory CLL

  • Industry update: Early-stage trials establish pathways for new treatment agents
     
  • More Coverage from ASH 2010

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.


Latest CME